| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L03 - Immunostimulants | Immunosuppressants, see L04A.
|
|
| L03A - Immunostimulants | Levamisole, which also affects the immune response, is classified in P02CE.
|
|
| L03AB - Interferons | Peginterferon alfa-2b in combination with ribavirin and peginterferon alfa-2a in combination with ribavirin are classified in L03AB60 and L03AB61, respectively.
| The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.
The DDDs of interferon beta-1a is based on i.m. administration.
|
|
| L03AB13 - Peginterferon Beta-1a | | Dose | Route of administration | Note |
|---|
| | P | |
|
|
